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Recombinant human erythropoietin stimulates angiogenesis
in vitro
RAUL G. CARLINI, ALVARO A. REYES, and Mcos RomsmIN
The Jewish Hospital of St. Louis, Washington University Medical Center Renal Division, St. Louis, Missouri, USA
Recombinant human erythropoietin stimulates angiogenesis in vitro.
Endothelial cell migration and proliferation are the key steps in the
angiogenic process, and both are stimulated by recombinant human
erythropoietin (rHuEPO). In addition rHuEPO can increase endothelin-1
(ET-1) release by the endothelial cell. We designed the present study to
address the question of whether rHuEPO stimulates angiogenesis. An in
vitro quantitative assay for angiogenesis was used. This consisted of rat
aortic rings embedded in a reconstituted basement membrane matrix and
incubated with and without rHuEPO for eight days. We found that
rHuEPO increased vessel outgrowth after four days of culture and this was
continued for the next four days (rHuEPO vs. control: day 4, 12 2 vs. 4
i,p < 0.002 and day 8, 124 18 vs. 56 12P < 0.006). Supernatant
endothelin-1 (ET-1) levels, at 24 hours, were significantly higher than
controls in the rings incubated with rHuEPO (107 13 vs. 43 10 pg/mI,P < 0.003). To investigate the role of ET-1 in rHuEPO-induced angio-
genesis, rings were exposed to ET-1 alone (10—8 M). We observed an
increase in microvessel formation compared to control (day 4, 4 2 vs. 2
1, P < 0.006, and day 8, 67 12 vs. 51 10, P < 0.03). In addition,
aortic rings were co-cultured with rHuEPO and anti-ET-1 IgG antibody.
Stimulation of angiogenesis by rHuEPO was blunted by the ET-1 anti-
body. We conclude that rHuEPO stimulates angiogenesis in vitro, and this
effect is due at least in part to the enhanced autocrine release of ET-1 by
rHuEPO.
Angiogenesis is the biological event in which preexisting vessels
give rise to new ones. This complex process is multifactorially
regulated. A plethora of stimulating angiogenic peptides have
been identified such as fibroblast growth factors, vascular endo-
thelial growth factor, epidermal growth factor, platelet-derived
growth factor, and angiogenin [1]. There are also a number of
inhibitors of angiogenesis including transforming growth factor f3,
tumor necrosis factor a, interferons and protamine [2]. Angiogen-
esis occurs in physiological and pathological conditions, for in-
stance the normal development of placenta, diabetic retinopathy,
tumor growth and chronic inflammatory states [3—5]. The angio-
genic process involves the degradation of the vascular basal
membrane by a protease, proliferation and migration of endothe-
hal cell (EC) through the extracellular matrix and pericyte
activation and alignment of the migrating cells to form a tubular
structure [6—8]. The rationale for the potential effect of rHuEPO
on EC derives from the fact that EC descend from angioblasts and
those in turn from mesenchymal cells. Also megakaryocytes and
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EC express similar antigenic features, and EC possesses an
erythropoietin receptor [9, 10]. We and others have shown that
recombinant human erythropoietin (rHuEPO) stimulates migra-
tion and proliferation, as well as endothelin-1 (ET-1) release by
EC [10, 11]. In the present study we tested the hypothesis that
rHuEPO induces angiogenesis using an in vitro model [12]. We
also determined whether the ET-1 release by rHuEPO played a
role in the rHuEPO associated angiogenesis.
Methods
Rat aortic rings
Thoracic aortas were obtained under halothane anesthesia
from one- to two-month-old Sprague-Dawley rats (200 to 250 g
body wt; Harlan, Indianapolis, IN, USA). The aortas were placed
in 35 mm cultured dishes (Falcon, Lincoln Park, NJ, USA)
containing serum free media (SFM): MCBD 131 (Clonetics, San
Diego, CA, USA). The fibroadipose tissue around the aorta was
removed using a dissecting microscope. The two segments of the
aorta used to hold the artery during the dissection were discarded.
The aortas were sectioned in 1 mm rings. The rings were rinsed
eight times with SFM.
Agarose rings
Agarose rings were made to give support to the gel of the
reconstitutive basement membrane matrix (Matrigel). Sterile
1.5% agarose (type VI-A; Sigma Chemical Co., St. Louis, MO,
USA) was poured into 110 X 15 mm cultured dish (35 mI/dish;
Falcon) and kept at room temperature for 15 minutes for gelation.
The agarose rings were cut using two custom-made nylon punch-
ers with a diameter of 17 and 10 mm, respectively. The punchers
were sterilized with methanol 100% before use. Two concentric
circles were made in the gel using the punchers. Each agarose ring
was placed in a 35 mm dish (Falcon).
Preparation of aortic culture
This method allows a rat aortic ring to grow microvessels in a
three-dimensional culture when placed between two layers of
basement membrane matrix. The bottom of the agarose rings
were filled with four drops of matrix, either Matrigel or Growth
Factor Reduced (GFR) Matrigel (Collaborative Biomedical
Products, Bedford, MA, USA), and allowed to gel for 30 minutes
at 37°C. Then, the aortic rings were placed in the center of the
matrix-coated agarose rings. Subsequently, the aortic tissue was
covered with Matrigel or GFR Matrigel matrix. After the matrix
gelation, the rings were incubated with 4 ml of SFM.
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Experimental groups
Quantification of angiogenesis
Endothelin-1 assay
* * Table 1. Angiogenic activity of 50 U/mI rHuEPO in rat aortic rings
4 Days 8 Days
Control rHuEPO Control rHuEPO
Matrigel 4 2 12 2 56 12 124 18
GFR Matrigel 2 1 9 3 47 7 98 10
The recovery capability of the assay is 85% with a 100% specificity
for ET-1.
Histological studies
Aortic rings embedded in Matrigel were fixed in 2% glutaral-
dehyde, post-fixed in 1% Osmium tetroxide, dehydrated and
embedded in Poly/Bed 812 resin. Thin sections were cut and
stained with uranyl acetate and lead citrate (PolyScience Inc.,
Warrington, PA, USA). The sections were examined using a light
microscope (Nikon).
Statistics
Values are expressed as the mean standard deviation (SD).
Analysis of variance (ANOVA) and Student's t-test by Instat
(GraphPAD Software, Inc., San Diego, CA) were used to com-
pare differences between experimental groups.
Results
Effect of rHuEPO on angiogenesis
As shown in Figure 1, the rings incubated with rHuEPO had a
significant increase in microvessel formation as compared to
controls (SFM). Dose-response experiments demonstrated that
the minimal dose of rHuEPO necessary to induce angiogenesis
was 50 U/ml (data not shown). Microvessel growth was detected
as early as the second day in the rHuEPO rings but not in the
controls. On day 4 the rings incubated with rHuEPO had a 250%
increase in angiogenesis over controls (12 2 vs. 4 1,
respectively; P < 0.001). This enhancement in growth was sus-
tained during the following three days of culture. By day 8
rHuEPO induced microvascular growth by 221% over control
(124 18 vs. 56 12, respectively; P < 0.006). The angiogenic
effect of rHuEPO was also compared using rHuEPO vehicle and
rHuEPO inactive peptide as controls. Significant differences in
vessel growth were found between rHuEPO and both controls
(data not shown). We also evaluated the angiogenic activity of
rHuEPO (50 U/ml) in rings embedded in GFR Matrigel, which
contains reduced concentrations of both basement membrane
compounds and growth factors. GFR Matrigel had less, but not
significantly different, microvessel formation than the Matrigel
(Table 1).
Figure 2 shows the aortic rings after four days of culture with
rHuEPO or SFM (control). rHuEPO-incubated rings (A) had an
increase in microvessel formation and branching compared to
control (B). Microvessels grew outward from the cut edges of the
aorta. Initially linear capillaries were observed during the first
four or five days followed by formation of polygonal networks.
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Fig. 1. Effect of rHuEPO on microvascular growth. Rat aortic rings em-
bedded in Matrigel were incubated in serum free media (..•",
control), and with rHuEPO (—A—, 50 U/mI) during 8 days. Bar and error
bars represent the mean SD of three experiments performed in
triplicate. * P < 0.002, ** P < 0.006.
Rat aortic rings were embedded in Matrigel and growth factor reduced
(GFR) Matrigel. Rings were incubated during 8 days with serum free
media (control) and with rHuEPO 50 U/mI. No differences between the
two groups were found. Values are mean SD of three experiments
performed in duplicate.
*
To the SFM the following agents were added: (1) rHuEPO 50
U/ml (Amgen, Inc., Thousand Oaks, CA, USA); (2) ET-1 10—8 M
(Peninsula Laboratories, Belmont, CA, USA); and (3) rHuEPO
50 U/mi + purified rabbit anti-ET-1 IgG antibody (anti-T-1 Ab,
10 j.Lg/ml), which have a 100% specificity for ET-1 (Peninsula
Laboratories, Inc.). Control rings were incubated with: SFM
alone; SFM + rHuEPO vehicle; SFM + rHuEPO inactive peptide
(1-26 equimolar concentration; Sigma); and SFM + nonimmune
rabbit IgG (10 jLg/ml) (Sigma). The media and conditions were
changed every other day, over eight days. The rings were incu-
bated at 37°C in a humidified 5% C02: 95% air atmosphere.
The rings were evaluated using an inverted microscope (Nikon,
Tokyo, Japan). Microvessel formation was assessed daily using the
following scoring criteria: (1) each single sprout was counted as
one microvessel; (2) the branches originated from a sprout were
counted individually; and (3) each loop was counted as two
microvessels since it was formed by the anastomosis of two
microvessels.
ET-1 was determined as previously described [11]. Briefly,
aortic rings were incubated with rHuEPO (50 U/mi) and SFM
alone (control) for 24 hours. Then the media was removed,
centrifuged at 2000 rpm for 10 minutes and the supernantants
were stored at —70°C. ET-1 was extracted using Sep-Pak C18
cartridges (Waters Assoc., Mildefor, MA, USA). The ET-1 assay
was performed using an ET-1 RIA kit (Peninsula Laboratories).
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Fig. 2. Rat aortic rings embedded in Matrigel
after 4 days of incubation with (A) rHuEPO 50
U/mi and with serum free media (control) (B).
Microvascular growth form the cutting edges of
the aortic ring. Magnification X25.
Figure 3 represents a cross section of the microvessels after eight
days of growth in Matrigel and rHuEPO.
Endothelin-1 promoting angiogenesis
rHuEPO-treated rings had greater production of ET-1 in the
culture media than controls after 24 hours (107 13 vs. 43 10
pg/mi, respectively; P < 0.003; Fig. 4). To test the effect of ET-1
on neovascular formation, aortic rings were exposed to different
concentrations of ET-1 (from 10—6 to 10—10 M). We found that
10_8 M ET-1 significantly increased angiogenesis as compared to
control (SFM), (day 4, 4 1 vs. 2 1; (P < 0.006; day 8, 67 12
vs. 51 10; P < 0.03). To clarify the role of ET-1 in the
rHuEPO-induced neovascularization aortic rings were incubated
with: rHuEPO; rHuEPO + anti-ET-1 Ab; and with SFM. As
shown in Figure 5, coincubation of rHuEPO + anti-ET-1 Ab
brought about a decrease in microvessel growth to a value similar
to controls (8 days, rHuEPO, 108 12 vs. rHuEPO + anti-ET-1;
Ab, 61 10, P < 0.001). Also, no differences were observed
between rings incubated with rHuEPO + non-immune IgG and
rHuEPO alone (Fig. 6).
Discussion
The present study demonstrates that rHuEPO induces angio-
genesis in vitro. The underlying mechanism of this effect is
unknown, but we favor the hypothesis that it can be related to the
rHuEPO increases in EC proliferation and migration. Also, the
interaction between the hormone and other growth factors such as
those contained in Matrigel may have a significant effect in our
angiogenesis model. The difference between the relatively high
angiogenic threshold of rHuEPO (50 UIml) and the therapeutic
plasma levels needed to promote erythrogenesis (1.7 to 3.6 U/mI)
should be viewed in the context of two entirely different processes
in different types of cells (vascular cells vs. erythroblast) [131.
Discrepancy between the in vivo and in vitro doses of endocrine
peptides, such as parathyroid and insulin-like growth factor-i, has
been reported [14, 15]. We confirm previous reports [16—18] that
rHuEPO increases the release of ET-1 in vitro and demonstrate
that this ET-i elevation mediates, at least in part, the rHuEPO
neovascularization effect.
ET-1 plasma levels are elevated in patients with atherosclerosis
z
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Fig. 3. A light microscopy photograph of a cross section of one of the microvessels. Aortic rings were embedded in Matrigel and cultured with rHuEPO
(50 U/mi) for 8 days. Surrounding cells forming a central lumen (star) which contain cellular debris. Magnification x 100.
after percutaneous transluminal coronary angioplasty and in
hemodialysis (HD) patients treated with intravenous rHuEPO
[19—21]. Atherosclerosis is a frequent complication in HD [22]
and is associated with high cardiovascular morbidity and mortality
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Fig. 5. Microvascular growth in rat aortic rings embedded in Matrigel and
incubated during 8 days with serum free media (•..., control), rHuEPO
(—A—, 50 U/mI), and rHuEPO + anti-ET-1 Ab (- -Ky-
-, 10 pg/mI). Bar and
error bars represent the mean SD of three experiments performed in
triplicate. rHuEPO vs. rHuEPO + anti-ET-1 Ab: *P < 0.03 ** P < 0.01.
[23]. A possible link between angiogenesis and atherosclerosis is
suggested by the observation that neovascularization of the vasa
vasorum is commonly observed in the atherosclerotic area [24].
Whether proliferation of the vasa vasorum precedes or follows
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Fig. 4. Effect of rHuEPO on ET-1 production in rat aortic rings embedded
in Matrigel and incubated in serum free media (4 control), and with
rHuEPO 50 U/mi (1111) during 24 hours. Bar and error bars represent the
mean so of three experiments performed in duplicate. * P < 0.003.
Time, days
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plaque formation is not known; however, these new vessels are
relatively fragile and when disrupted may cause medial hemor-
rhage of the atherosclerotic plaque increasing the risk of throm-
bosis. Recently 1251-ET-1 binding to the vasa vasorum or regions
of neovascularization has been shown in atherosclerotic blood
vessels [25]. Furthermore, ET-1 is recognized to induce pericytes
and smooth muscle cells proliferation (SMC) [26, 27]. The latter
has been implicated in neointimal proliferation and vascular
restenosis after balloon angioplasty in rats [28]. Giaid, Stewart
and Michael have demonstrated that in dogs with post-obstructive
pulmonary vasculopathies ET-1 induces proliferation of bronchial
collateral vessels, perhaps modulating bronchial neovasculariza-
tion and pulmonary arterial thickening [29]. Taken together these
data suggest that rHuEPO could have a deleterious effect on the
vascular endothelium, inducing angiogenesis and increasing ET-1
which is involved in atherosclerosis, hypertension and vascular
restenosis. A preliminary report [30] has suggested an increased
risk for cardiovascular and peripheral vascular disease in diabetic
patients undergoing continuous ambulatory peritoneal dialysis
when treated with rHuEPO. Nevertheless, in states of erythropoi-
etin up-regulation such as anemia of chronic disease (with normal
renal function) vasculopathy is not a common feature.
It is also conceivable that the angiogenic effect of rHuEPO
could be beneficial. The term "therapeutic angiogenesis" has been
proposed to describe the induction of neovascularization (using
angiogenic cytokines) for the treatment of hypovascular tissue
[31].
In conclusion, rHuEPO induced angiogenesis in vitro. This
effect may be mediated, at least in part, through the autocrine
release of ET-1. The clinical implications of our findings remain to
be elucidated.
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